

Resource Summary Report

Generated by NIF on Jul 29, 2026

Brilliant Violet 711(TM) anti-human CD19

RRID:AB_2562065

Type: Antibody

Proper Citation

BioLegend Cat# 302246, RRID:AB_2562065

Antibody Information

URL: http://antibodyregistry.org/AB_2562065

Proper Citation: BioLegend Cat# 302246, RRID:AB_2562065

Target Antigen: CD19

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 711(TM) anti-human CD19

Description: This monoclonal targets CD19

Target Organism: human

Clone ID: Clone HIB19

Antibody ID: AB_2562065

Vendor: BioLegend

Catalog Number: 302246

Alternative Catalog Numbers: 302245

Record Creation Time: 20250820T025603+0000

Record Last Update: 20250820T145423+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 711(TM) anti-human CD19.

No alerts have been found for Brilliant Violet 711(TM) anti-human CD19.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 8 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Melo Garcia L, et al. (2025) Overcoming CD226-related immune evasion in acute myeloid leukemia with CD38 CAR-engineered NK cells. Cell reports, 44(1), 115122.

Scharffenberger SC, et al. (2024) Targeting RSV-neutralizing B cell receptors with anti-idiotypic antibodies. Cell reports, 43(10), 114811.

Blaeschke F, et al. (2023) Modular pooled discovery of synthetic knockin sequences to program durable cell therapies. Cell, 186(19), 4216.

Malhi H, et al. (2022) Immunization with a self-assembling nanoparticle vaccine displaying EBV gH/gL protects humanized mice against lethal viral challenge. Cell reports. Medicine, 3(6), 100658.

Seydoux E, et al. (2021) Development of a VRC01-class germline targeting immunogen derived from anti-idiotypic antibodies. Cell reports, 35(5), 109084.

Kfoury Y, et al. (2021) Human prostate cancer bone metastases have an actionable immunosuppressive microenvironment. Cancer cell, 39(11), 1464.

Singh S, et al. (2020) Neutralizing Antibodies Protect against Oral Transmission of Lymphocryptovirus. Cell reports. Medicine, 1(3).

Cassetta L, et al. (2019) Human Tumor-Associated Macrophage and Monocyte Transcriptional Landscapes Reveal Cancer-Specific Reprogramming, Biomarkers, and Therapeutic Targets. Cancer cell, 35(4), 588.